Existing studies of PARP inhibition in NB have largely established its efficacy in specific tumor types, including those that amplify or overexpress MYCN, as well as those with 11q deletion and/or low ataxia-telangiectasia mutated (ATM) expression [16, 37–42]. Here, PARP1 is linked to neoplasm.